Search Tag: Janssen COVID-19 vaccine

Executive Health Management


2021 05 Mar

The European Medicines Agency (EMA) has launched a rolling review of the Russian Sputnik V vaccine and is convening to potentially finalise the COVID-19 Vaccine Janssen’s marketing authorisation.   You might also like: The European Ombudsman is investigating the European Commission’s refusal to give public access to...Read more

Executive Health Management


2021 21 Apr

The European Medicines Agency has completed its safety review for Johnson & Johnson’s COVID-19 Vaccine Janssen giving conclusions similar to those on AstraZeneca’s Vaxzevria.   You might also like: EMA announced that the single dose Covid-19 vaccine has been approved for use in individuals 18 years of age and older in the European...Read more

Executive Health Management


2021 22 Sep

In July, New York University researchers published results (Tada et. al, 2021) indicating the one-shot Johnson & Johnson (J&J) vaccine was less effective at preventing Delta variant infections. Although the study is not yet peer-reviewed, this finding is troubling given that the Delta variant now accounts for most US COVID-19 cases. Booster doses were...Read more

Executive Health Management


2021 19 Oct

On Friday, 15 October, a U.S. FDA advisory committee unanimously recommended that all adults that received the Johnson & Johnson (J&J) COVID-19 vaccine get a booster shot at least two months after their first shot. J&J now joins Pfizer and Moderna in gaining an FDA recommendation for a booster.   Unlike the Pfizer and Moderna recommendations which...Read more